Adenosine A1 Receptor Protein

Adenosine A1 Receptor Protein

Introduction

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Adenosine A1 Receptor Protein</th>
</tr>
<tr>
<td class="label">Domain</td>
<td>Residues</td>
</tr>
<tr>
<td class="label">N-terminus</td>
<td>1-50</td>
</tr>
<tr>
<td class="label">TM1</td>
<td>51-75</td>
</tr>
<tr>
<td class="label">TM2</td>
<td>76-99</td>
</tr>
<tr>
<td class="label">TM3</td>
<td>100-129</td>
</tr>
<tr>
<td class="label">TM4</td>
<td>130-154</td>
</tr>
<tr>
<td class="label">TM5</td>
<td>155-181</td>
</tr>
<tr>
<td class="label">TM6</td>
<td>182-208</td>
</tr>
<tr>
<td class="label">TM7</td>
<td>209-232</td>
</tr>
<tr>
<td class="label">C-terminus</td>
<td>233-326</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">Phosphorylation</td>
<td>Desensitization</td>
</tr>
<tr>
<td class="label">Arrestin binding</td>
<td>Internalization</td>
</tr>
<tr>
<td class="label">Receptor degradation</td>
<td>Downregulation</td>
</tr>
<tr>
<td class="label">mRNA changes</td>
<td>Reduced expression</td>
</tr>
<tr>
<td class="label">Region</td>
<td>Density</td>
</tr>
<tr>
<td class="label">Cerebral [cortex](/brain-regions/cortex)</td>
<td>High</td>
</tr>
<tr>
<td class="label">[Hippocampus](/brain-regions/hippocampus)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Cerebellum

Adenosine A1 Receptor Protein

Introduction

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Adenosine A1 Receptor Protein</th>
</tr>
<tr>
<td class="label">Domain</td>
<td>Residues</td>
</tr>
<tr>
<td class="label">N-terminus</td>
<td>1-50</td>
</tr>
<tr>
<td class="label">TM1</td>
<td>51-75</td>
</tr>
<tr>
<td class="label">TM2</td>
<td>76-99</td>
</tr>
<tr>
<td class="label">TM3</td>
<td>100-129</td>
</tr>
<tr>
<td class="label">TM4</td>
<td>130-154</td>
</tr>
<tr>
<td class="label">TM5</td>
<td>155-181</td>
</tr>
<tr>
<td class="label">TM6</td>
<td>182-208</td>
</tr>
<tr>
<td class="label">TM7</td>
<td>209-232</td>
</tr>
<tr>
<td class="label">C-terminus</td>
<td>233-326</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">Phosphorylation</td>
<td>Desensitization</td>
</tr>
<tr>
<td class="label">Arrestin binding</td>
<td>Internalization</td>
</tr>
<tr>
<td class="label">Receptor degradation</td>
<td>Downregulation</td>
</tr>
<tr>
<td class="label">mRNA changes</td>
<td>Reduced expression</td>
</tr>
<tr>
<td class="label">Region</td>
<td>Density</td>
</tr>
<tr>
<td class="label">Cerebral [cortex](/brain-regions/cortex)</td>
<td>High</td>
</tr>
<tr>
<td class="label">[Hippocampus](/brain-regions/hippocampus)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Cerebellum</td>
<td>High</td>
</tr>
<tr>
<td class="label">Spinal cord</td>
<td>High</td>
</tr>
<tr>
<td class="label">Thalamus</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Basal ganglia</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Selectivity</td>
</tr>
<tr>
<td class="label">Adenosine</td>
<td>Non-selective</td>
</tr>
<tr>
<td class="label">CCPA</td>
<td>A1 selective</td>
</tr>
<tr>
<td class="label">CPA</td>
<td>A1 selective</td>
</tr>
<tr>
<td class="label">Selodenoson</td>
<td>A1 selective</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Selectivity</td>
</tr>
<tr>
<td class="label">Caffeine</td>
<td>Non-selective</td>
</tr>
<tr>
<td class="label">Theophylline</td>
<td>Non-selective</td>
</tr>
<tr>
<td class="label">Rolofylline</td>
<td>A1 selective</td>
</tr>
<tr>
<td class="label">BG9719</td>
<td>A1 selective</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">5 edges</a></td>
</tr>
</table>

Adenosine A1 Receptor Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

The Adenosine A1 Receptor (A1R) is a Gi/o protein-coupled receptor that inhibits adenylate cyclase, reduces cAMP levels, and hyperpolarizes [neurons](/entities/neurons) through GIRK channel activation. This 326-amino acid protein is the most abundant adenosine receptor in the brain and serves as the primary mediator of adenosine's inhibitory effects on neuronal excitability. A1R is widely expressed throughout the central and peripheral nervous systems, where it regulates neurotransmitter release, controls pain transmission, modulates sleep-wake cycles, and provides neuroprotection during metabolic stress. Dysregulation of A1R signaling contributes to epilepsy, chronic pain, sleep disorders, and neurodegenerative diseases.

Protein Structure

Structural Architecture

A1R follows the canonical seven-transmembrane GPCR fold:

Ligand Binding

The orthosteric binding site is located within the transmembrane bundle:

• Endogenous ligand: Adenosine (micromolar affinity)
• Key binding residues: Hydrophobic and polar interactions
• Allosteric sites: Cholesterol and other allosteric modulators

Molecular Function

Signal Transduction

A1R couples primarily to Gi/o proteins, activating multiple downstream pathways:

Primary Signaling Cascade

Adenosine binding → A1R conformational change → Gi/o activation
↓
┌─────────┴─────────┐
↓ ↓ ↓
Adenylyl GIRK N-type
cyclase channels Ca²⁺ channels
↓ ↓ ↓
cAMP↓ Hyperpolar- Ca²⁺ influx↓
ization

Secondary Signaling Pathways

• phospholipase C activation (via Gq, minor pathway)
• MAPK activation (via βγ subunits)
• PI3K/Akt pathway (cell survival signaling)

Receptor Regulation

Expression and Localization

Brain Distribution

A1R shows widespread but region-specific expression:

Cellular Localization

• Presynaptic terminals: Inhibitory autoreceptor
• Postsynaptic dendrites: Hyperpolarizing response
• [Astrocytes](/entities/astrocytes): Glial signaling
• [Microglia](/entities/microglia): Immunomodulation

Disease Mechanisms

Epilepsy

A1R provides endogenous seizure protection:

• Hyperexcitability reduction: Limits glutamate release
• Seizure termination: Adenosine release during seizures
• Therapeutic potential: A1R agonists as anti-convulsants
• Tolerance concern: Chronic use leads to receptor desensitization

Chronic Pain

A1R mediates adenosine-induced analgesia:

• Peripheral analgesia: Direct nerve terminal effects
• Spinal analgesia: Reduces dorsal horn transmission
• Descending modulation: Activates pain-inhibitory pathways
• Clinical translation: Oral A1 agonists limited by side effects

Neurodegeneration

A1R alterations in AD and PD:

• [Alzheimer's Disease](/diseases/alzheimers-disease): Reduced A1R density in cortex
• [Parkinson's Disease](/diseases/parkinsons-disease): Altered striatal A1R signaling
• Neuroprotection: A1R activation reduces excitotoxicity
• Cognitive effects: A1R blockade may enhance cognition

Sleep Disorders

• Sleep pressure: Adenosine accumulation promotes sleep
• Sedative effects: A1R agonism induces sleep
• Caffeine mechanism: Primarily A2a (not A1) antagonism

Therapeutic Targeting

Agonists

Antagonists

Allosteric Modulators

• Advantages: Greater selectivity, reduced desensitization
• Examples: Several compounds in pre-clinical development
• Challenge: Achieving brain penetration

Animal Model Findings

Knockout Studies

• A1R-/- mice: Increased seizure susceptibility
• Pain behavior: Aligned nociceptive responses
• Sleep: REM sleep abnormalities

Pharmacological Studies

• A1R agonists: Anticonvulsant, analgesic, sleep-inducing
• A1R antagonists: Wake-promoting, cognitive enhancement

Research Directions

Background

The study of Adenosine A1 Receptor Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

[1]: https://pubmed.ncbi.nlm.nih.gov/10629201/ PMID: 10629201(https://pubmed.ncbi.nlm.nih.gov/10629201/)
[2]: https://pubmed.ncbi.nlm.nih.gov/10816402/ PMID: 10816402(https://pubmed.ncbi.nlm.nih.gov/10816402/)
[3]: https://pubmed.ncbi.nlm.nih.gov/15604288/ PMID: 15604288(https://pubmed.ncbi.nlm.nih.gov/15604288/)
[4]: https://pubmed.ncbi.nlm.nih.gov/17585956/ PMID: 17585956(https://pubmed.ncbi.nlm.nih.gov/17585956/)
[5]: https://pubmed.ncbi.nlm.nih.gov/19029120/ PMID: 19029120(https://pubmed.ncbi.nlm.nih.gov/19029120/)
[6]: https://pubmed.ncbi.nlm.nih.gov/21885568/ PMID: 21885568(https://pubmed.ncbi.nlm.nih.gov/21885568/)
[7]: https://pubmed.ncbi.nlm.nih.gov/22949693/ PMID: 22949693(https://pubmed.ncbi.nlm.nih.gov/22949693/)
[8]: https://pubmed.ncbi.nlm.nih.gov/25666150/ PMID: 25666150(https://pubmed.ncbi.nlm.nih.gov/25666150/)

See Also

• [ADORA1 Gene](/genes/adora1)
• [Adenosine A2a Receptor Protein](/proteins/adora2a-protein)
• [G](/mechanisms/dopaminergic-neuron-vulnerability)
• [Epilepsy](/diseases/epilepsy)
• [Chronic Pain](/mechanisms/dopaminergic-neuron-vulnerability)
• [Sleep Disorders](/therapeutics/sleep-disorders-neurodegeneration)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [UniProt: ADORA1](https://www.uniprot.org/uniprot/P30542)
• [PDB: A1R Structure](https://www.rcsb.org/structure/5N2S)
• [GeneCards: ADORA1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=ADORA1)
• [IUPHAR: A1 Receptor](https://www.guidetopharmacology.org/GTOPage.php?topId=12)